1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. INmune Bio, Inc.
  6. Summary
    INMB   US45782T1051

INMUNE BIO, INC.

(INMB)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
10.39 USD   +0.78%
08/04INMUNE BIO : Announces Second Quarter 2022 Results and Provides Business Update - Form 8-K
PU
08/03Earnings Flash (INMB) INMUNE BIO Reports Q2 Revenue $16,000
MT
08/03Earnings Flash (INMB) INMUNE BIO Posts Q2 Loss $-0.38
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
9.03(c) 9.71(c) 10.05(c) 10.31(c) 10.39(c) Last
39 007 98 663 64 349 55 153 83 854 Volume
+0.67% +7.53% +3.50% +2.59% +0.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 0,12 M - -
Net income 2022 -30,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,11x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -53,3 M - -
Net Debt 2023 - - -
P/E ratio 2023 -5,72x
Yield 2023 -
Capitalization 186 M 186 M -
Capi. / Sales 2022 1 541x
Capi. / Sales 2023 -
Nbr of Employees 10
Free-Float 64,9%
More Financials
Company
INmune Bio, Inc. is a clinical-stage biotechnology pharmaceutical company. The Company is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). It has two product platforms. The DN-TNF product platform utilizes... 
More about the company
Ratings of INmune Bio, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about INMUNE BIO, INC.
08/04INMUNE BIO : Announces Second Quarter 2022 Results and Provides Business Update - Form 8-K
PU
08/03Earnings Flash (INMB) INMUNE BIO Reports Q2 Revenue $16,000
MT
08/03Earnings Flash (INMB) INMUNE BIO Posts Q2 Loss $-0.38
MT
08/03TRANSCRIPT : INmune Bio, Inc., Q2 2022 Earnings Call, Aug 03, 2022
CI
08/03INMUNE BIO, INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/03INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update
AQ
08/03INmune Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended J..
CI
07/27MANAGEMENT TO HOST CONFERENCE CALL A : 30 pm ET on that day - Form 8-K
PU
07/27INMUNE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/27INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporat..
GL
07/25INMUNE BIO : Alzheimer's Association International Conference (“AAIC”) –..
PU
07/25INMUNE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/25INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alz..
GL
07/25INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alz..
GL
06/23INMUNE BIO : USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases..
PU
More news
News in other languages on INMUNE BIO, INC.
08/03Earnings Flash (INMB) INMUNE BIO annonce un revenu de 16 000 $ pour le deuxième trimest..
08/03INmune Bio, Inc. annonce ses résultats pour le deuxième trimestre et les six mois termi..
06/22INmune Bio reçoit un brevet américain couvrant l'utilisation d'un traitement contre les..
05/24MISE À JOUR SECTORIELLE : Les actions du secteur de la santé retrouvent un terrain positif..
05/24MISE À JOUR SECTORIELLE : Soins de santé
More news
Analyst Recommendations on INMUNE BIO, INC.
More recommendations
Chart INMUNE BIO, INC.
Duration : Period :
INmune Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INMUNE BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 10,39 $
Average target price 14,33 $
Spread / Average Target 38,0%
EPS Revisions
Managers and Directors
Raymond J. Tesi Chairman, President, Chief Executive Officer & CMO
David J. Moss Chief Financial Officer, Secretary & Treasurer
Mark Lowdell Director
J. Kelly Ganjei Independent Director
Timothy J. Schroeder Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INMUNE BIO, INC.1.86%186
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093